Press Release February 17, 2022 The merger of Cerba Research and Viroclinics-DDL Together, transforming diagnostics for clinical trials. After the acquisition of Viroclinics-DDL by the group Cerba Healthcare, we are delighted to announce that Cerba Research, the...
PRESS RELEASE Cerba Healthcare enters agreement to acquire Viroclinics-DDL expanding and transforming its offering in clinical trials Acquisition illustrates the Group’s strategy to strengthen its position in the entire value chain of diagnosis and stresses the...
PRESS RELEASE Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network ROTTERDAM, Netherlands and OSLO, Norway, 14 December 2021: Today, Viroclinics-DDL, a global...
Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its oral PARP inhibitor, stenoparib, against Coronavirus variant B.1.617.2 (delta variant). Article Open the...
